PRESS RELEASES

Date Title and Summary View
Toggle Summary GlycoMimetics Posters at 60th ASH Annual Meeting Highlight Preclinical Data on Two New Proprietary Drug Candidates
ROCKVILLE, Md. --(BUSINESS WIRE)--Dec. 4, 2018-- GlycoMimetics, Inc. (NASDAQ: GLYC) shared at the 60 th American Society of Hematology (ASH) Annual Meeting yesterday two posters with preclinical data presentations: on GMI-1687, the company’s highly potent E-selectin antagonist that is bioavailable
View HTML
Toggle Summary GlycoMimetics Presents New AML Data with Uproleselan at 60th ASH Annual Meeting
Data in relapsed/refractory and newly diagnosed acute myeloid leukemia (AML) patients underscore clinical opportunities across multiple outcomes measures and subgroups Selective disruption of bone marrow microenvironment with uproleselan resulting in high remission rates; majority of evaluable
View HTML
Toggle Summary GlycoMimetics to Host 2018 Investor/Analyst Meeting at 60th ASH Annual Meeting on December 3, 2018
ROCKVILLE, Md. --(BUSINESS WIRE)--Nov. 29, 2018-- GlycoMimetics, Inc.  (NASDAQ: GLYC) announced today that it will host and webcast an investor/analyst meeting and update at the 60th  American Society of Hematology (ASH) Annual Meeting in San Diego, on December 3 at 6 a.m. PT . Daniel J.
View HTML
Toggle Summary Scott Jackson, Veteran Biopharmaceutical Executive, Joins GlycoMimetics Board of Directors
ROCKVILLE, Md. --(BUSINESS WIRE)--Nov. 28, 2018-- GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that it has appointed Scott Jackson , former Chief Executive Officer of  Celator Pharmaceuticals, Inc. , to its Board of Directors. Mr. Jackson served as Celator’s CEO and as a member of its Board
View HTML
Toggle Summary GlycoMimetics Enrolls First Patient in Global Phase 3 Clinical Trial of Uproleselan in Relapsed/Refractory Acute Myeloid Leukemia
Pivotal Trial to Evaluate Efficacy and Safety of Uproleselan in Patients with Advanced Acute Myeloid Leukemia (AML); Trial to Enroll 380 Patients at US and International Sites Broad Late-stage Development Program in Place to Evaluate Uproleselan Across the Continuum of Care in AML ROCKVILLE, Md.
View HTML
Toggle Summary GlycoMimetics Reports Third Quarter 2018 Results and Highlights Recent Company Achievements
Continued to select new clinical sites and ready previously-selected sites in the U.S., Europe , Canada and Australia for the company-sponsored Phase 3 pivotal trial in relapsed/refractory AML; study now open for enrollment Received notice of Japanese patent issuance in August for uproleselan
View HTML
Toggle Summary GlycoMimetics to Present Analyses from Phase 1/2 AML Trial of Uproleselan at 60th ASH Meeting
New and updated clinical outcomes data and subgroup analyses continue to demonstrate potential benefit of treatment with uproleselan when added to chemotherapy 69 percent (11 out of 16) of evaluable patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) and 56 percent (5 out of 9) of
View HTML
Toggle Summary GlycoMimetics to Report Third Quarter 2018 Financial Results on November 2, 2018
ROCKVILLE, Md. --(BUSINESS WIRE)--Oct. 26, 2018-- GlycoMimetics, Inc. (NASDAQ: GLYC) announced today that it will host a conference call and webcast to provide a corporate update and report its third-quarter 2018 financial results on Friday, November 2, 2018 , at 8:30 a.m. ET .
View HTML
Toggle Summary GlycoMimetics to Present at Upcoming Investor Conferences
ROCKVILLE, Md. --(BUSINESS WIRE)--Oct. 24, 2018-- GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Chief Executive Officer Rachel King will provide a company overview at two upcoming investor conferences, as follows: STIFEL 2018 HEALTHCARE CONFERENCE When: November 13, 2018 at 10:15 a.m.
View HTML
Toggle Summary GlycoMimetics Receives Japanese Patent For Uproleselan (GMI-1271)
Issued patent expands global patent portfolio for GlycoMimetics’ late-stage drug candidate targeting treatment of broad spectrum of patients with acute myeloid leukemia (AML) ROCKVILLE, Md. --(BUSINESS WIRE)--Aug. 14, 2018-- GlycoMimetics, Inc. (NASDAQ: GLYC), a biopharmaceutical company focused on
View HTML